General Dermatology
Eczema
Chronic Hand Eczema
Alopecia
Aesthetics
Vitiligo
COVID-19
Actinic Keratosis
Precision Medicine and Biologics
Rare Disease
Wound Care
Rosacea
Psoriasis
Psoriatic Arthritis
Atopic Dermatitis
Melasma
NP and PA
Skin Cancer
Hidradenitis Suppurativa
Drug Watch
Pigmentary Disorders
Acne
Pediatric Dermatology
Practice Management
Prurigo Nodularis

The Evolution of Topical PDE4 Inhibitors in Treating Atopic Dermatitis : Episode 2

Opinion

Video

November 15, 2024

PDE4 Inhibitor Roflumilast for AD

Author(s):

Lisa Swanson, MD, FAAD,Benjamin Lockshin, MD, FAAD

Key Takeaways

Nonsteroidal topical treatments for atopic dermatitis have gained prominence, reducing reliance on steroids and their associated side effects.
PDE4 inhibitors block phosphodiesterase 4, decreasing pro-inflammatory cytokine production and mitigating inflammation in atopic dermatitis.
The evolution of nonsteroidal options reflects a broader trend towards targeted therapies in dermatology, offering improved safety profiles and efficacy.

Panelists discuss the current landscape of topical treatments for atopic dermatitis, focusing on the evolution of nonsteroidal options over the past decade, and explain the mechanism of action of PDE4 inhibitors in specifically targeting inflammatory pathways associated with the condition.

EP: 1.Evolution of Topical Treatment for AD

Now Viewing

EP: 2.PDE4 Inhibitor Roflumilast for AD

Can you provide an overview of the current landscape of topical treatments for atopic dermatitis and how these options, specifically nonsteroidal options, have evolved over the past decade?
What is the mechanism of action of PDE4 inhibitors, and how do they specifically target the inflammatory pathways in atopic dermatitis?